The U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp) plus Revlimid (lenalidomide) and Rituxan ...
WASHINGTON (Reuters) - Survival rates have improved in the United States for children with three common types of blood cancer since the 1990s, thanks to improved treatment, researchers in Germany said ...
ROCHESTER, N.Y. (WROC) — A groundbreaking Hodgkin lymphoma study from the University of Rochester Medical Center showed a 92% survival rate with fewer side effects and reduced radiation therapy use.
Pharmaceutical Technology on MSN
FDA approves AbbVie’s Epkinly to treat follicular lymphoma
The US Food and Drug Administration (FDA) has approved AbbVie’s Epkinly (epcoritamab-bysp) to treat adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback